Other Indications |  Print This Page  |  Resources For US Healthcare Professionals

Weeks 12-52: Sustained Response
Peak clinical response to CIMZIA was achieved at Week 12 and sustained through Week 521

Significant, sustained ACR response1,3
In RAPID 1, ACR response rates continued to increase after Weeks 4 and to be significantly higher in patients receiving CIMZIA compared with placebo.1,2 Once response peaked, the improvements were generally sustained through Week 52.1,2 Similar results were seen in RAPID 2.3
  • ACR20 response:
    • Maximum response rate for both CIMZIA groups was achieved at Week 121
    • Response at Week 24 (co-primary efficacy end point) was 58.8% in the CIMZIA 200 mg group compared with 13.6% for placebo (P<.001).1 Differences in responses remained significant through Week 521
  • ACR50 and ACR70 response (CIMZIA 200 mg group):
    • Maximum response rates (both measures) were achieved by Weeks 14 through 201
    • Responses at Week 24 (major secondary efficacy end points) were 37% (ACR50) and 21% (ACR70)1
RAPID 1: Significant ACR Response at Week 12 Lasting to
Week 52 (ITT pop.)1,2*

Click to enlarge
*P<.001. Placebo + MTX values were 18%, 7%, and 2% for ACR20/50/70, respectively, at Week 12.

Significant, sustained reduction in swollen and tender joints1,2
Swollen and tender joint counts also continued to improve rapidly from Week 4 to Week 12 in patients receiving CIMZIA, with improvements sustained at Weeks 24 and 52 and differences significant compared with placebo.1 Similar results were seen in RAPID 2.3


RAPID 1: Significant Reduction in Total Number of Swollen and Tender Joints at Week 12 Lasting to Week 52 (ITT pop.)1,2†

Click to enlarge
Similar results were seen in RAPID 2.
†P<.001. Placebo + MTX value was –11% for both reduction in tender joint count and reduction in swollen joint count at Week 12. (Negative percentage indicates a decrease in tender/swollen joint count.)


Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF-blockers.


References:
1. Keystone E, Heijde D, Mason D Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58:3319-3329.
2. Data on file. UCB, Inc.; Smyrna, GA.
3. Smolen JS, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomized controlled trial. Ann Rheum Dis. 2009;68:797-804.
Your patients may be
eligible to save up to
$500 per pack on
CIMZIA prescriptions